Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MDWD
stocks logo

MDWD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.88M
+34.91%
-0.594
+65%
6.28M
+58.7%
-0.597
+752.39%
6.77M
+18.66%
-0.580
-52.85%
Estimates Revision
The market is revising Downward the revenue expectations for MediWound Ltd. (MDWD) for FY2025, with the revenue forecasts being adjusted by -3.84% over the past three months. During the same period, the stock price has changed by 10.37%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-27.66%
In Past 3 Month
Stock Price
Go Up
up Image
+10.37%
In Past 3 Month
Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30.33 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30.33 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.980
sliders
Low
25.00
Averages
30.33
High
36.00
Current: 17.980
sliders
Low
25.00
Averages
30.33
High
36.00
H.C. Wainwright
Buy
maintain
$31 -> $36
2025-11-21
Reason
H.C. Wainwright
Price Target
$31 -> $36
2025-11-21
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$36 -> $34
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$36 -> $34
2025-06-02
downgrade
Outperform
to
Outperform
Reason
Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.
H.C. Wainwright
Swayampakula Ramakanth
Buy
upgrade
$25 -> $31
2025-05-22
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$25 -> $31
2025-05-22
upgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on MediWound to $31 from $25 and keeps a Buy rating on the shares following the Q1 report.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$25
2025-03-20
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$25
2025-03-20
Reiterates
Strong Buy
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Initiates
$39
2025-02-28
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$39
2025-02-28
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$25
2025-01-10
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$25
2025-01-10
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mediwound Ltd (MDWD.O) is -7.56, compared to its 5-year average forward P/E of -8.37. For a more detailed relative valuation and DCF analysis to assess Mediwound Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.37
Current PE
-7.56
Overvalued PE
-4.51
Undervalued PE
-12.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.52
Undervalued EV/EBITDA
-11.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.28
Current PS
0.00
Overvalued PS
7.21
Undervalued PS
3.34
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MDWD News & Events

Events Timeline

(ET)
2025-11-20
07:01:41
MediWound Announces Q3 Earnings Per Share of 24 Cents, Below Consensus Estimate of 98 Cents
select
2025-11-03 (ET)
2025-11-03
08:16:41
MediWound Finalizes Launch of Enhanced GMP Manufacturing Facility
select
2025-09-29 (ET)
2025-09-29
08:42:16
MediWound reveals $30 million registered direct offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-21Benzinga
Palo Alto Set to Surge by 30%? Check Out 10 Leading Analyst Predictions for Friday

  • Analyst Downgrades: Baird downgraded Bath & Body Works Inc from Outperform to Neutral, lowering the price target from $33 to $19, while also cutting Jacobs Solutions Inc's target from $161 to $146 and downgrading it to Neutral.

  • Analyst Upgrades: Goldman Sachs upgraded Helmerich and Payne Inc from Sell to Neutral, raising its price target from $20 to $28, and B of A Securities maintained a Buy rating for Block Inc, increasing its target from $86 to $88.

  • Price Target Increases: Needham raised the price target for Kulicke And Soffa Industries Inc from $40 to $46, and BTIG increased Walmart Inc's target from $120 to $125, both maintaining Buy ratings.

  • Mixed Ratings: Ascendiant Capital cut Plus Therapeutics Inc's target from $21 to $19 while keeping a Buy rating, and Morgan Stanley reduced Brightview Holdings Inc's target from $16 to $12, maintaining an Equal-Weight rating.

[object Object]
Preview
6.0
11-21Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for MediWound, Increases Price Target to $36

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
9.5
11-20Newsfilter
MediWound Announces Financial Results for Q3 2025 and Shares Corporate Developments

  • Clinical Trials and Product Development: MediWound is advancing its VALUE Phase III trial of EscharEx for venous leg ulcers, with enrollment ongoing across 40 sites in the U.S. and Europe, while also preparing to initiate a clinical trial for diabetic foot ulcers in 2026.

  • Financial Performance: The company reported a 23% year-over-year revenue increase to $5.4 million for Q3 2025, driven by higher development service revenue, and a net loss reduction to $2.7 million compared to $10.3 million in the same quarter of 2024.

  • Manufacturing Expansion: The commissioning of an expanded NexoBrid manufacturing facility has been completed, expected to reach full operational capacity by the end of 2025, significantly increasing production capacity to meet global demand.

  • Equity Financing and Balance Sheet Strength: MediWound strengthened its balance sheet with a $30 million equity financing, resulting in $60 million in cash and equivalents as of September 30, 2025, positioning the company for continued growth and development initiatives.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mediwound Ltd (MDWD) stock price today?

The current price of MDWD is 17.98 USD — it has increased 1.52 % in the last trading day.

arrow icon

What is Mediwound Ltd (MDWD)'s business?

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

arrow icon

What is the price predicton of MDWD Stock?

Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30.33 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mediwound Ltd (MDWD)'s revenue for the last quarter?

Mediwound Ltd revenue for the last quarter amounts to 5.43M USD, increased 24.66 % YoY.

arrow icon

What is Mediwound Ltd (MDWD)'s earnings per share (EPS) for the last quarter?

Mediwound Ltd. EPS for the last quarter amounts to -0.24 USD, decreased -75.51 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mediwound Ltd (MDWD)'s fundamentals?

The market is revising Downward the revenue expectations for MediWound Ltd. (MDWD) for FY2025, with the revenue forecasts being adjusted by -3.84% over the past three months. During the same period, the stock price has changed by 10.37%.
arrow icon

How many employees does Mediwound Ltd (MDWD). have?

Mediwound Ltd (MDWD) has 111 emplpoyees as of December 05 2025.

arrow icon

What is Mediwound Ltd (MDWD) market cap?

Today MDWD has the market capitalization of 226.81M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free